TRANSGENE SA (TNG.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:TNG - FR0005175080 - Common Stock
TNG.PA Key Statistics, Chart & Performance
The current stock price of TNG.PA is 0.964 EUR. In the past month the price increased by 2.34%. In the past year, price increased by 34.55%.
TNG.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TNG.PA. When comparing the yearly performance of all stocks, TNG.PA turns out to be only a medium performer in the overall market: it outperformed 48.84% of all stocks.
TNG.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TNG.PA. TNG.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
TNG.PA Financial Highlights
Over the last trailing twelve months TNG.PA reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -31.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.88% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TNG.PA Forecast & Estimates
7 analysts have analysed TNG.PA and the average price target is 1.5 EUR. This implies a price increase of 55.19% is expected in the next year compared to the current price of 0.964.
For the next year, analysts expect an EPS growth of 55.56% and a revenue growth 4.56% for TNG.PA
TNG.PA Ownership
TNG.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.45 | 43.00B | ||
| ARGX.BR | ARGENX SE | 65.32 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.17B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.06B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.09B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.93B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.94B | ||
| IVA.PA | INVENTIVA SA | N/A | 1.01B | ||
| 6IV.DE | INVENTIVA SA | N/A | 962.73M | ||
| NANO.PA | NANOBIOTIX | N/A | 886.20M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| PHIL.MI | PHILOGEN SPA | 18.99 | 633.05M |
Related stock screener links
About TNG.PA
Company Profile
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 147 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Company Info
TRANSGENE SA
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166, Cedex
Illkirch-Graffenstaden GRAND EST FR
Employees: 144
Phone: 33388279100
TRANSGENE SA / TNG.PA FAQ
What does TRANSGENE SA do?
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 147 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
What is the stock price of TRANSGENE SA today?
The current stock price of TNG.PA is 0.964 EUR. The price decreased by -0.41% in the last trading session.
What is the dividend status of TRANSGENE SA?
TNG.PA does not pay a dividend.
How is the ChartMill rating for TRANSGENE SA?
TNG.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for TNG.PA stock?
7 analysts have analysed TNG.PA and the average price target is 1.5 EUR. This implies a price increase of 55.19% is expected in the next year compared to the current price of 0.964.
What is the ownership structure of TRANSGENE SA (TNG.PA)?
You can find the ownership structure of TRANSGENE SA (TNG.PA) on the Ownership tab.